ABI 02
Alternative Names: ABI-02Latest Information Update: 23 Nov 2022
At a glance
- Originator Avanti Biosciences
- Class Catechins; Small molecules
- Mechanism of Action DYRK kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Down syndrome
Most Recent Events
- 23 Nov 2022 Early research in Down syndrome in USA (unspecified route) before November 2022 (Avanti Biosciences pipeline, November 2022)